Skip to main content

NF1

2
Pipeline Programs
4
Companies
5
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 3 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
Poly ICLCPhase 21 trial
Active Trials
NCT04544007Terminated3Est. Nov 2024
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
ImlygicPhase 11 trial
Active Trials
NCT07102394Recruiting10Est. Dec 2027
Medtronic
MedtronicNJ - Phillipsburg
1 program
INFUSE Bone GraftN/A1 trial
Active Trials
NCT02718131Terminated5Est. Jun 2020
SpringWorks Therapeutics
1 program
MirdametinibPHASE_1_2Small Molecule2 trials
Active Trials
NCT07539441Recruiting26Est. Oct 2029
NCT06159166Recruiting24Est. Nov 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Angeles TherapeuticsPoly ICLC
SpringWorks TherapeuticsMirdametinib
SpringWorks TherapeuticsMirdametinib
AmgenImlygic
MedtronicINFUSE Bone Graft

Clinical Trials (5)

Total enrollment: 68 patients across 5 trials

A Phase II Trial of Poly-ICLC for Low-Grade Gliomas

Start: Feb 2022Est. completion: Nov 20243 patients
Phase 2Terminated

A Study of Mirdametinib in People With Central Nervous System Tumors

Start: Apr 2026Est. completion: Oct 202926 patients
Phase 1/2Recruiting

Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).

Start: Feb 2024Est. completion: Nov 202824 patients
Phase 1/2Recruiting

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

Start: Feb 2026Est. completion: Dec 202710 patients
Phase 1Recruiting
NCT02718131MedtronicINFUSE Bone Graft

A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)

Start: Mar 2016Est. completion: Jun 20205 patients
N/ATerminated

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 actively recruiting trials targeting 68 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.